Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Chelsea Beiser

Physician Assistant, Medical Katy, TX Physician Assistant

NPI 1497297394 CMS profile 10537975

25230 Kingsland Blvd Ste 102, Katy, TX 77494

Open in the dashboard

General payments

$17,986

883 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Chelsea Beiser of Katy, TX is reported in the CMS Open Payments database as having received $17,986 across 883 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,516 165
2024 General $4,086 189
2023 General $3,892 159
2022 General $3,262 179
2021 General $3,230 191

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Chelsea Beiser
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to Chelsea Beiser were reported at $3,516. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year Chelsea Beiser Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $3,230 $156 $41–$563 $132
2022 $3,262 $185 $55–$649 $149
2023 $3,892 $199 $58–$717 $160
2024 $4,086 $206 $62–$740 $164
2025 $3,516 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $3,854 213 payments
  2. Takeda Pharmaceuticals U.S.A., Inc. $1,757 89 payments
  3. Janssen Biotech, Inc. $1,691 77 payments
  4. Regeneron Healthcare Solutions, Inc. $1,600 31 payments
  5. Salix Pharmaceuticals, a division of Bausch Health US, LLC $1,425 89 payments
  6. QOL Medical, LLC $822 44 payments
  7. Celgene Corporation $682 53 payments
  8. Pfizer Inc. $561 31 payments
  9. Madrigal Pharmaceuticals $524 17 payments
  10. RedHill Biopharma Inc. $466 27 payments
  11. Other $4,604 212 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $17,127 877 payments
  2. Consulting Fee $810 3 payments
  3. Education $49 3 payments
Products named General payments · program years 2021–2025
  1. STELARA $1,407 59 payments
  2. DUPIXENT $1,363 23 payments
  3. ENTYVIO $1,334 64 payments
  4. CREON $1,231 67 payments
  5. RINVOQ $1,158 70 payments
  6. LINZESS $1,091 65 payments
  7. SKYRIZI $1,036 52 payments
  8. XIFAXAN $936 56 payments
  9. ZEPOSIA $910 55 payments
  10. TREMFYA $782 25 payments
  11. Other $9,775 522 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 8 drugs

Part D claims

288

Median for Physician Assistant: 241

Drug cost

$54,248

Median for Physician Assistant: $4,110

Branded share of claims

16.3%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Linzess Linaclotide Brand 34 $32,208
Mesalamine Generic 26 $9,189
Dexlansoprazole Dr Dexlansoprazole Brand 13 $6,068
Rabeprazole Sodium Generic 27 $2,947
Omeprazole Generic 115 $1,718
Colestipol Hcl Generic 25 $1,407
Pantoprazole Sodium Generic 30 $431
Famotidine Generic 18 $280

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 31 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUPIXENT
$406 — —
SKYRIZI
$329 — —
STELARA
$308 — —
LINZESS
$304 34 —
RINVOQ
$248 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 31 with Patron

Records

883 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Medical in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record